280 related articles for article (PubMed ID: 36594109)
1. Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Dai J; Liu X; Li J; Qu T; Cui Y; Jin S; Zhang E; Guo R
Thorac Cancer; 2023 Feb; 14(6):535-543. PubMed ID: 36594109
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.
Zhang S; Li S; Liu J; Yang C; Zhang L; Bao H; Cheng Y
Clin Lung Cancer; 2022 Mar; 23(2):159-169. PubMed ID: 34247986
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
[TBL] [Abstract][Full Text] [Related]
4. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
6. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
Deng Z; Qin Y; Liu Y; Zhang Y; Lu Y
Clin Lung Cancer; 2021 Jan; 22(1):e70-e83. PubMed ID: 33067126
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced
Chen F; Chen N; Yu Y; Cui J
Front Oncol; 2020; 10():904. PubMed ID: 32714857
[No Abstract] [Full Text] [Related]
8. First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
Mosca M; Conci N; Di Federico A; Tateo V; Favorito V; Zappi A; Gelsomino F; De Giglio A
JCO Precis Oncol; 2023 May; 7():e2300073. PubMed ID: 37262392
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
10. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.
Huang L; Huang H; Zhou XP; Liu JF; Li CR; Fang M; Wu JR
Medicine (Baltimore); 2019 Oct; 98(43):e17705. PubMed ID: 31651902
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
16. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
Yan H; Li Q; Wang W; Zhen H; Cao B
Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.
Hu D; Zhou YY; Ma HB; Tao MM; Huang QZ; Yang ZZ; Zhou Q
BMC Pulm Med; 2023 Jun; 23(1):207. PubMed ID: 37316870
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis.
Zhang L; Ren HW; Wu QL; Wu YJ; Song X
Pathol Oncol Res; 2020 Apr; 26(2):1137-1143. PubMed ID: 31147837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]